CClinicalTrials.gg
RecruitingNCT06063798FlowjetUpdated Oct 3, 2023

Respiratory Effects of Flow-Controlled Ventilation and Jet Ventilation in Patients Undergoing Laryngotracheal Surgery

An interventional study of General anesthesia for laryngotracheal surgery and Mechanical ventilation by FCV in Ventilation, Lung Function and Anesthesia, General, sponsored by University Hospital, Geneva. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by University Hospital, Geneva · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Laryngotracheal surgery often requires a small diameter endotracheal tube to oxygenate patients under general anesthesia. Oxygenation is often only possible with high-frequency jet ventilators due to the use of small diameter and high resistance airway cannulas.

Flow controlled ventilation is a new ventilation modality capable for ventilation through a small diameter endotracheal tube (Tritube) with an active expiratory phase and the possibility of controlled carbon dioxide elimination during mechanical ventilation.

The aim of the present trial is to characterize perioperative changes in lung volume, ventilation inhomogeneity and respiratory mechanics in patients undergo upper airway surgery under general anesthesia with either flow controlled or high-frequency jet ventilation.

Read the detailed description

This study is a randomized, controlled, assessor blind, monocentric study.

A new ventilation mode, called Flow Controlled Ventilation (FCV), has been suggested to minimize the amount of dissipated energy in the lungs and potentially could be protective during mechanical ventilation. FCV is unique in creating a stable gas flow into and also out of the patient's lungs to generate inspiration and expiration respectively. The FCV ventilation mode by its design allows the use of an ultrathin endotracheal tube with an inflatable cuff to secure the airways for ventilation. Therefore FCV offers several new surgical options for the treatment during laryngeal and tracheal surgery where the standard approach is usually the use of high-frequency jet ventilation (HFJV). The limitations of HFJV are however the lack of airway protection, limited monitoring of the respiratory variables and potential carbon dioxide (CO2) accumulation.

Participants for this study will be recruited at the University Hospitals of Geneva, scheduled for laryngotracheal surgery under general anesthesia. A total of 50 patients will be enrolled and randomly assigned into 2 groups: Group FCV (Flow controlled ventilation) and Group HFJV (high-frequency jet ventilation).

Measurements of functional residual capacity (FRC) and lung clearance index (LCI) will be performed in patients with a nitrogen multiple breath washout method, before and approximately 1 hour after surgery. Similarly, respiratory system resistance (R) and respiratory reactance (X) will be measured at the same time by using the Forced Oscillation Technique.

Relevance: There are no studies that addressed the value of flow controlled ventilation in terms of lung function parameters (FRC and LCI) and lung mechanics (R, X) in comparison to high-frequency jet ventilation in patients undergoing upper airway surgery.

02

Conditions studied

  • Ventilation
  • Lung Function
  • Anesthesia, General

Keywords

  • Flow-controlled ventilation
  • High frequency jet ventilation
  • Lung protection
  • Laryngotracheal surgery
03

In context

Lead sponsor

University Hospital, Geneva is the lead sponsor of 372 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Informed Consent signed by the subject
  • General anesthesia for laryngotracheal surgery
  • Adult patients, female and male, over 18 years of age
  • Elective surgery

Exclusion criteria

Exclusion Criteria:

  • Documented severe heart conditions (New York Heart Association Class 4, severe pulmonary hypertension)
  • Documented severe respiratory disease (uncontrolled asthma, severe pulmonary fibrosis, chronic obstructive pulmonary disease GOLD 4)
  • Documented severe Neurological diseases (Acute ischemic and hemorrhagic stroke within the preceding 3 months, uncontrolled seizures)
  • Surgery that requires tracheotomy
  • Obesity (Body Mass Index ≥ 30 kg/m2)
  • Inability to follow the procedures of the study (mental condition or language barrier e.g. incomprehension of French language)
  • Previous enrolment into the current study or other study that involves unknown medication in the past 12 months
  • Allergy or contraindication to Propofol and/or Remifentanil and/or Rocuronium
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Flow Controlled Ventilation Group

    Ventilation by Flow Controlled Ventilation mode Patient is scheduled for elective laryngotracheal surgery under general anesthesia. The ventilation mode for this group is Flow Controlled Ventilation mode.

    Other: General anesthesia for laryngotracheal surgery · Other: Mechanical ventilation by FCV

  • Active comparator
    High Frequency Jet ventilation Group

    Ventilation by High Frequency Jet ventilation mode Patient is scheduled for elective laryngotracheal surgery under general anesthesia. The ventilation mode for this group is High Frequency Jet ventilation mode.

    Other: General anesthesia for laryngotracheal surgery · Other: Mechanical ventilation by HFJV

Interventions

  • OtherGeneral anesthesia for laryngotracheal surgery

    Patients undergoing general anesthesia and mechanical ventilation.

  • OtherMechanical ventilation by FCV

    Mechanical ventilation is assured by Flow-controlled ventilation mode.

  • OtherMechanical ventilation by HFJV

    Mechanical ventilation is assured by High frequency jet ventilation mode.

06

What researchers measure

Primary outcomes

  1. Alterations in the functional residual capacity (FRC)

    FRC measured by the nitrogen multiple breath washout technique that will be applied before and after general anesthesia

    Time frame: Right before general anesthesia and approximately 1 hour after general anesthesia or before discharge from post anesthesia care unit

Secondary outcomes

  1. Alterations in the Lung clearance index (LCI)

    LCI measured by the nitrogen multiple breath washout technique that will be applied before and after general anesthesia

    Time frame: Right before general anesthesia and approximately 1 hour after general anesthesia or before discharge from post anesthesia care unit

  2. Alterations in the respiratory resistance assessed by the forced oscillation technique (FOT)

    Respiratory mechanics will be measured by the forced oscillation technique (FOT) to evaluate respiratory resistance (R).

    Time frame: Right before general anesthesia and approximately 1 hour after general anesthesia or before discharge from post anesthesia care unit

  3. Alterations in the respiratory reactance assessed by the forced oscillation technique (FOT)

    Respiratory mechanics will be measured by the forced oscillation technique (FOT) to evaluate respiratory reactance (X).

    Time frame: Right before general anesthesia and approximately 1 hour after general anesthesia or before discharge from post anesthesia care unit

Other outcomes

  1. Changes in mean blood pressure

    mean blood pressure (mmHg)

    Time frame: Intraoperative period with specific time points: before anesthesia induction, at the beginning of the surgery, at the end of surgery, right after extubation

  2. Changes in heart rate

    heart rate (beat per minute)

    Time frame: Intraoperative period with specific time points: before anesthesia induction, at the beginning of the surgery, at the end of surgery, right after extubation

  3. Changes in oxygen saturation

    Oxygen saturation will be measured by pulse oximetry (%)

    Time frame: Intraoperative period with specific time points: before anesthesia induction, at the beginning of the surgery, at the end of surgery, right after extubation

  4. Changes in transcutaneous carbon dioxide

    Transcutaneous carbon dioxide will be measured

    Time frame: Intraoperative period with specific time points: before anesthesia induction, at the beginning of the surgery, at the end of surgery, right after extubation

07

Study locations

1 of 1 sites recruiting
  • Geneva University Hospitals
    Geneva, 1211, Switzerland
    Recruiting
08

References and documents

Publications

  • Neder JA, Andreoni S, Castelo-Filho A, Nery LE. Reference values for lung function tests. I. Static volumes. Braz J Med Biol Res. 1999 Jun;32(6):703-17. doi: 10.1590/s0100-879x1999000600006. PubMed 10412549 ↗
  • Bourgain JL, Chollet M, Fischler M, Gueret G, Mayne A; membres du conseil du club en anesthesie en ORL. [Guide for the use of jet-ventilation during ENT and oral surgery]. Ann Fr Anesth Reanim. 2010 Oct;29(10):720-7. doi: 10.1016/j.annfar.2010.06.020. Epub 2010 Sep 15. French. PubMed 20833503 ↗
  • Bacher A, Pichler K, Aloy A. Supraglottic combined frequency jet ventilation versus subglottic monofrequent jet ventilation in patients undergoing microlaryngeal surgery. Anesth Analg. 2000 Feb;90(2):460-5. doi: 10.1097/00000539-200002000-00041. PubMed 10648340 ↗
  • Barnes T, van Asseldonk D, Enk D. Minimisation of dissipated energy in the airways during mechanical ventilation by using constant inspiratory and expiratory flows - Flow-controlled ventilation (FCV). Med Hypotheses. 2018 Dec;121:167-176. doi: 10.1016/j.mehy.2018.09.038. Epub 2018 Sep 24. PubMed 30396474 ↗
  • Tonetti T, Vasques F, Rapetti F, Maiolo G, Collino F, Romitti F, Camporota L, Cressoni M, Cadringher P, Quintel M, Gattinoni L. Driving pressure and mechanical power: new targets for VILI prevention. Ann Transl Med. 2017 Jul;5(14):286. doi: 10.21037/atm.2017.07.08. PubMed 28828361 ↗
  • Cressoni M, Gotti M, Chiurazzi C, Massari D, Algieri I, Amini M, Cammaroto A, Brioni M, Montaruli C, Nikolla K, Guanziroli M, Dondossola D, Gatti S, Valerio V, Vergani GL, Pugni P, Cadringher P, Gagliano N, Gattinoni L. Mechanical Power and Development of Ventilator-induced Lung Injury. Anesthesiology. 2016 May;124(5):1100-8. doi: 10.1097/ALN.0000000000001056. PubMed 26872367 ↗
  • Schmidt J, Wenzel C, Mahn M, Spassov S, Cristina Schmitz H, Borgmann S, Lin Z, Haberstroh J, Meckel S, Eiden S, Wirth S, Buerkle H, Schumann S. Improved lung recruitment and oxygenation during mandatory ventilation with a new expiratory ventilation assistance device: A controlled interventional trial in healthy pigs. Eur J Anaesthesiol. 2018 Oct;35(10):736-744. doi: 10.1097/EJA.0000000000000819. PubMed 29734208 ↗
  • Meulemans J, Jans A, Vermeulen K, Vandommele J, Delaere P, Vander Poorten V. Evone(R) Flow-Controlled Ventilation During Upper Airway Surgery: A Clinical Feasibility Study and Safety Assessment. Front Surg. 2020 Feb 28;7:6. doi: 10.3389/fsurg.2020.00006. eCollection 2020. PubMed 32185179 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06063798
Lead sponsor
University Hospital, Geneva
Responsible party
Dr. Gergely Albu (Principal investigator, University Hospital, Geneva) — Principal investigator
First posted
Oct 3, 2023
Start date
Sep 5, 2023
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 3, 2023

Study contacts

Gergely Albu, MD, PhD
Contact
gergely.albu@hcuge.ch
0041795532052
Gergely Albu, MD, PhD
principal investigator · University Hospital, Geneva

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion